Clearside Biomedical, Inc. (NASDAQ:CLSD) is reporting third quarter financial results on Tuesday 10th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, CLSD is expected to report 3Q20 loss of $ 0.12 per share from revenue of $ 1.82 million.
For the full year, analysts anticipate top line of $ 8.38 million, while looking forward to loss of $ 0.42 per share bottom line.
Previous Quarter Performance
Clearside Biomedical, Inc. unwinded loss for the second quarter of $ 0.13 per share, from the revenue of $ 0.35 million. The quarterly revenues up 600.00 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.12 per share from $ 1.33 million in revenue. The bottom line results missed street analysts by $ 0.01 or 8.33 percent, at the same time, top line results fell short of analysts by $ 0.98 million or 73.68 percent.
Stock Performance
Shares of Clearside Biomedical, Inc. traded up $ 0.02 or 1.49 percent on Monday, reaching $ 1.36 with volume of 155.50 thousand shares. Clearside Biomedical, Inc. has traded high as $ 1.39 and has cracked $ 1.28 on the downward trend
According to the previous trading day, closing price of $ 1.36, representing a 39.58 % increase from the 52 week low of $ 0.96 and a 67.55 % decrease over the 52 week high of $ 4.13.
The company has a market capital of $ 63.03 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Clearside Biomedical, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.clearsidebio.com
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
